Skip to main content

Table 1 Demographic and baseline medical characteristics (ME population)

From: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  Tigecycline N = 247 Imipenem/Cilastatin N = 255
Mean ± SD age, years 42.9 ± 18.0 43.1 ± 17.6
Sex, n (%) male 173 (70.0) 166 (65.1)
Ethnic origin, n (%)   
   White 104 (42.1) 106 (41.6)
   Black 16 (6.5) 25 (9.8)
   Asian 30 (12.1) 30 (11.8)
   Hispanic 54 (21.9) 44 (17.3)
   Other 43 (17.4) 50 (19.6)
Mean ± SD weight, kg 70.3 ± 15.7 69.3 ± 15.9
Mean ± SD creatinine clearance, mL/min 94.2 ± 35.3 94.3 ± 34.1
Mean ± SD therapy duration, days 8.1 ± 2.8 7.9 ± 2.7
Mean APACHE II score 5.6 5.5
Primary intra-abdominal diagnosis, n (%)   
   Complicated appendicitis 152 (61.5) 145 (56.9)
   Perforation of intestine 21 (8.5) 23 (9.0)
   Complicated diverticulitis 17 (6.9) 25 (9.8)
   Intra-abdominal abscess 17 (6.9) 17 (6.7)
   Peritonitis 14 (5.7) 16 (6.3)
   Gastric/duodenal perforation 13 (5.3) 10 (3.9)
   Complicated cholecystitis 12 (4.9) 16 (6.3)
   Other* 1 (0.4) 3 (1.2)
  1. *Other diagnoses included infected hematoma, pelvic inflammatory disease, acute abdomen subocclusion, acute inflammatory abdomen, disease pelvic infectious, tubo-ovarian abscess, right tubal abscess, infected left subphrenic hematoma.